Competitor Analysis: Obesity & Diabetes

La Merie Publishing, March 2007, Pages: 72

Product description The present Competitive Intelligence Report provides a competitor evaluation in the field of molecules used to treat diabetes as of March 2007. The competitor evaluation of Molecules to treat diabetes compiles parts of our Competitor Analysis Series which previously have been published in R&D Pipeline News, vol.3, 2007. Competitor projects are listed in a tabular format providing Information on:

Information is provided on:

Drug Codes, Target / Mechanism of Action, Class of Compound, Company, Product Category Indication, R&D Stage and additional comments with a hyperlink leading to the source of information.

Chapter 1: Obesity

CB1
Selective 5-HT2c Receptor Agonists
Selective 5-HT6 Receptor Antagonists
Monoamine-related Mechanism of Action
Pro-opiomelanocortin (POMC) & Melanin-related Mechanism of Action
Protein tyrosine phosphatase-1B (PTP-1B) Inhibitors
PPAR Agonists
Thyroid Hormone Receptor Modulators
SGLT-2 Inhibitors
Microsomal triglyceride transfer protein inhibitors
Various
Anti-Obesity peptides
Anti-Obesity Biologics

Chapter II: Insulin

Insulin Market: Sales 2006
Inhaled Insulin
Nasal Insulin
Transdermal Insulin
Oral Insulin
Engineered Insulin
Long-Acting Insulin
Follow-On Insulin

Chapter III: PPAR Agonists

1st Generation PPAR Gamma Agonists
Next Generation PPAR Gamma Agonists
PPAR Alpha Agonists (Fibrate Type)
PPAR Alpha Agonists
Discontinued PPAR Alpha Agonists
Dual PPAR Alpha And Gamma Agonists
Discontinued Dual PPAR Alpha ? Gamma Agonists
Triple PPAR Alpha, Gamma & Delta (Pan) Agonists

Chapter IV: DPP-IV

DPP-IV
DPP-IV Discontinued or No Further Activities

Chapter V: GLP-1
Chapter VI: SGLT Inhibitors
Chapter VII: Emerging Diabetes Drugs
About la Merie Business Intelligence

The present Competitive Intelligence Report provides a competitor evaluation in the field of molecules used to treat diabetes as of March 2007

Customers who bought this item also bought

• Type 2 Diabetes (Event Driven)
• Pipeline Insight: Non-insulin Antidiabetics - Rise of the weight-reducers: Once-weekly GLP-1 agonists and novel SGLT-2 inhibitors bring added benefits to diabetes therapy.
• Pipeline Insight: Non-insulin Antidiabetics - Rise of the weight-reducers
• Thought Leader Insight & Analysis Report - Diabetes/Obesity Q4 2010
• The Global Diabetes Market: Therapeutics, Diagnostics and Complications
• Competitor Analysis - Targeted Therapy of Obesity
• Exploring New Opportunities in the Expanding Diabetes Market: Novel Targets and Strategies
• U.S. Diabetes Pipeline Outlook
• Key Findings from Treatment Algorithms: Type 2 Diabetes
• The Diabetes Market Outlook: Market Analysis of Future Growth and Leading Players by Sector